Lilly's Oral Glp-1, Orforglipron, Showed Compelling Efficacy And A Safety Profile Consistent With Injectable Glp-1 Medicines, In Complete Phase 3 Results Published In The New England Journal Of Medicine

Eli Lilly and Co LLY:

• LILLY'S ORAL GLP-1, ORFORGLIPRON, SHOWED COMPELLING EFFICACY AND A SAFETY PROFILE CONSISTENT WITH INJECTABLE GLP-1 MEDICINES, IN COMPLETE PHASE 3 RESULTS PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

• ELI LILLY AND CO - ORFORGLIPRON LOWERS A1C BY 1.3% TO 1.6% IN PHASE 3 TRIAL

• ELI LILLY AND CO - REMAINS ON TRACK TO SUBMIT ORFORGLIPRON FOR WEIGHT MANAGEMENT BY END OF YEAR